Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Davids on Checkpoint Blockade Inhibition in Hematologic Malignancies After Stem Cell Transplant

December 10th 2017

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation.

Case Study 2: Options for Biochemically Relapsed MM

December 8th 2017

Case Study 2: An Elderly Patient With Multiple Myeloma

December 8th 2017

Case Study 1: The Value of KRd in Multiple Myeloma

December 8th 2017

Case Study 1: Treating MM After RVd and Transplant

December 8th 2017

Case Study 1: Follow-Up Strategies for Multiple Myeloma

December 8th 2017

Case Study 1: A Diagnosis of Stage II Multiple Myeloma

December 8th 2017

Multiple Myeloma: Second Relapse and Beyond

December 8th 2017

Multiple Myeloma: Considerations in Treating Relapse

December 8th 2017

Multiple Myeloma: Using Novel Therapies at Relapse

December 8th 2017

Multiple Myeloma: Understanding and Treating Progression

December 8th 2017

Maintenance Therapy's Value in Multiple Myeloma

December 8th 2017

Multiple Myeloma: Optimizing Approaches to Transplant

December 8th 2017

The Current Role of Transplant in Multiple Myeloma

December 8th 2017

Understanding Treatment Planning in Multiple Myeloma

December 8th 2017

Strategies for Upfront Therapy in Multiple Myeloma

December 8th 2017

Multiple Myeloma: Upfront Therapy and Longer Remissions

December 8th 2017

Increasingly Improved Outcomes for Multiple Myeloma

December 8th 2017

Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017

December 8th 2017

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

FDA Lifts Holds on 2 Nivolumab Myeloma Trials

December 6th 2017

The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.